Bacterial protein or nucleic acid Overview
"Bacterial protein or nucleic acid" is not a specific molecular target but rather a broad category encompassing numerous essential macromolecules within bacteria that serve as the basis for antibacterial drug action. These include structural and enzymatic proteins involved in processes such as cell wall biosynthesis (e.g., penicillin-binding proteins), ribosomal subunits responsible for translation/protein synthesis, enzymes required for folate metabolism and mycolic acid production, as well as bacterial DNA and RNA which are targeted by drugs interfering with replication or transcription machinery. Many classes of antibiotics act on these targets through diverse mechanisms—such as inhibiting peptidoglycan cross-linking in the cell wall; blocking translation at the ribosome; disrupting membrane integrity; or inhibiting key steps in nucleic acid metabolism—resulting in bacteriostatic or bactericidal effects depending on the class. Because "Bacterial protein/nucleic acid" is not a single molecule but an umbrella term covering many distinct targets with different structures and functions across various bacterial species, it is considered an imprecise designation for structured data purposes. Each individual target within this group should ideally be specified more precisely—for example "DNA gyrase," "30S ribosomal subunit," "penicillin-binding protein," etc.—to enable accurate mapping to drugs/mechanisms/disease roles/safety concerns.[1][2][4] This entry should be flagged as incorrect due to its lack of specificity—it refers collectively to many unrelated molecules rather than one canonical therapeutic target.
Mechanism of Action
Inhibition of cell wall biosynthesis by binding to penicillin-binding proteins or peptidoglycan subunits/enzyme inhibition Inhibition of protein synthesis via 30S or 50S ribosomal subunit binding Disruption of membrane integrity Inhibition of nucleic acid synthesis by targeting RNA polymerase or DNA gyrase/topoisomerase
Biological Functions
Disease Associations
Safety Considerations
- Off-target effects on host microbiota leading to dysbiosis and secondary infections such as C. difficile colitis
- Development of resistance mechanisms in bacteria including target modification and drug inactivation